64Cu与68Ga标记的GRPR靶向化合物RM2与AMTG的临床前比较及[68Ga]Ga-AMTG首次人体PET/CT
本研究在PC-3细胞和小鼠模型上比较了[64Cu]Cu-/[68Ga]Ga-AMTG与参考化合物[64Cu]Cu-/[68Ga]Ga-RM2的GRPR亲和力、内化与体内分布,并在1例转移性去势抵抗性前列腺癌患者中进行了[68Ga]Ga-AMTG首次人体PET/CT。结果显示AMTG适合诊疗一体化应用,需进一步临床评估。
要点
- AMTG与RM2均具高GRPR亲和力(半数抑制浓度1.5-4.0 nM)和高受体结合分数(79%-84%细胞相关活性)。
- 小鼠注射后1小时PC-3肿瘤摄取14.1-15.1 %ID/g,胰腺12.6-30.7 %ID/g,两种64Cu标记物肝摄取升高。
- [68Ga]Ga-AMTG在1例转移性去势抵抗性前列腺癌患者中显示多个病灶浓聚,证实临床前药代动力学特征。
核心结论
- AMTG适合诊疗一体化应用,因为用64Cu、68Ga以及既往研究已知的177Lu标记均不影响其良好的生物分布模式,需进一步临床评估。
研究设计与样本
- 临床前比较研究:在PC-3细胞上检测GRPR亲和力与内化,在PC-3荷瘤小鼠注射后1小时行生物分布研究,并开展1例前列腺癌患者的首次人体[68Ga]Ga-AMTG PET/CT概念验证研究。
主要发现
- 64Cu和68Ga标记几乎定量完成(>98%)。
- 所有化合物GRPR亲和力相近(半数抑制浓度1.5-4.0 nM),受体结合分数高(79%-84%细胞相关活性)。
- 小鼠注射后1小时PC-3肿瘤摄取14.1-15.1 %ID/g,胰腺12.6-30.7 %ID/g;除两种64Cu标记物肝摄取升高外,其他脱靶蓄积低。
- 总体生物分布和肿瘤/本底比值可比,但多数器官中68Ga标记类似物略优。
- [68Ga]Ga-AMTG在1例转移性去势抵抗性前列腺癌患者中显示多个病灶浓聚。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the recent success of prostate-specific membrane antigen (PSMA)-targeted compounds for theranostic use in prostate cancer (PCa), alternative options for the detection and treatment of PSMA-negative lesions are needed. We have recently developed a novel gastrin-releasing peptide receptor (GRPR) ligand with improved metabolic stability, which might improve diagnostic and therapeutic efficacy and could be valuable for PSMA-negative PCa patients. Our aim was to examine its suitability for theranostic use. We performed a comparative preclinical study on [64Cu]Cu-/[68Ga]Ga-AMTG ([64Cu]Cu-/[68Ga]Ga-α-Me-l-Trp8-RM2) using [64Cu]Cu-/[68Ga]Ga-RM2 ([64Cu]Cu-/[68Ga]Ga-DOTA-Pip5-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2) as a reference compound and investigated [68Ga]Ga-AMTG in a proof-of-concept study in a PCa patient. Methods: Peptides were labeled with 64Cu (80 °C, 1.0 M NaOAc, pH 5.50) and 68Ga (90 °C, 0.25 M NaOAc, pH 4.50). GRPR affinity (half-maximal inhibitory concentration, room temperature, 2 h) and GRPR-mediated internalization (37 °C, 60 min) were examined on PC-3 cells. Biodistribution studies were performed at 1 h after injection in PC-3 tumor-bearing mice. For a first-in-humans application, 173 MBq of [68Ga]Ga-AMTG were administered intravenously and whole-body PET/CT scans were acquired at 75 min after injection. Results: 64Cu- and 68Ga-labeling proceeded almost quantitatively (>98%). All compounds revealed similarly high GRPR affinity (half-maximal inhibitory concentration, 1.5-4.0 nM) and high receptor-bound fractions (79%-84% of cell-associated activity). In vivo, high activity levels (percentage injected dose per gram) were found in the PC-3 tumor (14.1-15.1 %ID/g) and the pancreas (12.6-30.7 %ID/g), whereas further off-target accumulation was low at 1 h after injection, except for elevated liver uptake observed for both 64Cu-labeled compounds. Overall biodistribution profiles and tumor-to-background ratios were comparable but slightly enhanced for the 68Ga-labeled analogs in most organs. [68Ga]Ga-AMTG confirmed the favorable pharmacokinetics-as evident from preclinical studies-in a patient with metastasized castration-resistant PCa showing intense uptake in several lesions. Conclusion: AMTG is eligible for theranostic use, as labeling with 64Cu and 68Ga, as well as 177Lu (known from previous study), does not have a negative influence on its favorable biodistribution pattern. For this reason, further clinical evaluation is warranted.
引用
- Koller L, Joksch M, Schwarzenböck S, et al. Preclinical Comparison of the 64Cu- and 68Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [68Ga]Ga-AMTG PET/CT. J Nucl Med. 2023. PMID: 37934025. doi:10.2967/jnumed.123.265771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。